ArticleJournal of medical biochemistry2025
The clinical value of inflammatory factors in evaluating the prognosis of patients with acute myeloid leukemia.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dysregulation of IL-37/SIGIRR Axis in De Novo acute myeloid leukemia patients: association with treatment response.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To assess the importance of inflammatory factors in predicting outcomes in individuals diagnosed with acute myeloid leukemia. Methods: Between July 2017 and December 2019, a total of 100 patients with a recent diagnosis of acute myeloid leukemia (AML) were recruited from the Hematology Department of our hospital's Cancer Center and assigned to the AML group. Additionally, 60 individuals with no underlying health conditions who underwent standard medical checkups during the same period were selected as the control group. Serum levels of IL-2, IL-4, IL-17A, TNF-a, IFN-g, and LIF were measured through ELISA. All participants in the AML group were followed up for three years. Based on the European Leukemia Network (ELN) genetic risk stratification criteria, patients were categorized into favorable, intermediate, and adverse prognosis subgroups. Inflammatory marker profiles were then compared among these subgroups. Results: Compared to healthy individuals, the AML group presented significantly increased serum concentrations of IL-4, IL-17A, and TNF-a, while levels of IL-2, IFN-g, and LIF were significantly decreased (P < 0.05). Upon stratifying patients by prognostic classification, those in the favorable and intermediate prognosis categories exhibited notably lower IL-4, IL-17A, and TNF-a levels relative to the poor prognosis group (all P < 0.05). In contrast, levels of IL-2, IFN-g, and LIF were notably elevated in the subgroup with favorable prognostic profiles (all P < 0.05). Additional analysis of cytokine expression indicated that increased levels of IL-4, IL-17A, and TNF-a were linked to worse 3-year survival performance (P < 0.05). Conversely, higher expression of IL-2, IFN-g, and LIF was significantly associated with better long-term survival outcomes relative to patients with reduced expression levels (P < 0.05). Conclusions: The abnormal levels of IL-4, IL-17A, TNF-a, IFNg and LIF in patients with acute myeloid leukemia are increased, while the abnormal levels of IL-2, IFNg and LIF are decreased, which has certain guiding effect on prognosis assessment and can be used as auxiliary indicators for prognosis assessment of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.